PALVELLA THERAPEUTICS, INC.
Clinical-stage biopharma developing topical therapies for rare genetic skin diseases.
PVLA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US7207951036
- LEI:
- Country:
- United States of America
- Address:
- 353 W. LANCASTER AVENUE, 19087 WAYNE
- Website:
- https://palvellatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients suffering from serious, rare genetic skin diseases (genodermatoses). The company's approach targets the underlying root causes of these conditions. Its lead product candidate, QTORIN rapamycin, is a patented, topical mTOR inhibitor. QTORIN is in late-stage clinical development for the treatment of debilitating skin diseases driven by the overactivation of the mTOR pathway, including microcystic lymphatic malformations (Phase 3) and cutaneous venous malformations (Phase 2).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all PALVELLA THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for PALVELLA THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for PALVELLA THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
